Early red blood cell transfusion strategy in septic shock among patients with cancer: the TRANSPORT randomized controlled trial
Intensive Care Medicine · 2026
DOI: 10.1007/s00134-026-08582-4 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Intensive Care Medicine, 2026. Verfasst von Frédéric Pène und 29 weiteren Autor:innen. Beteiligte Einrichtung: Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive-Réanimation, Medical Intensive Care Unit, Hôpital Cochin, Université Paris Cit…. Hauptthemen laut MEDLINE: Erythrocyte Transfusion, Neoplasms, Shock, Septic. Die Arbeit nennt 35 Literaturangaben. Gefördert von: French Ministry of Health.
Themen: Sepsis
Abstract (Originalsprache)
PURPOSE: Septic shock in cancer patients remains associated with a grim prognosis. With regard to the high prevalence of anemia, the optimal hemoglobin target to restore tissue oxygenation remains uncertain. METHODS: This was a multicenter superiority randomized controlled trial carried out in 18 centers in France. Adult patients with hematological or solid malignancies presenting with septic shock with lactate level > 2.0 mmol/L and hemoglobin level < 9.0 g/dL were randomly assigned to liberal or restrictive red blood cell (RBC) transfusion directed by hemoglobin thresholds of 9.0 g/dL or 7.0 g/dL during the first 48 h of resuscitation. The primary endpoint was 12-h lactate reduction, defined as normalization ≤ 2.0 mmol/L or relative decrease by 30% from baseline. Key secondary endpoints included ICU-acquired infections, arterial and venous thrombotic events, and 28-day mortality. RESULTS: The trial was designed to enroll 260 patients but was prematurely stopped for safety concerns. Finally, 187 patients were enrolled, distributed into 93 in the liberal arm and 94 in the restrictive arm. Twelve-hour lactate reduction was achieved in 52% and 50% of patients in the liberal and restrictive arms, respectively (odds ratio 1.07; 95% confidence interval 0.60 to 1.90; P = 0.82). Arterial or venous thrombotic events occurred more frequently in the liberal group (13% vs. 1%; P = 0.001), and 28-day mortality rates were 46% and 53% (P = 0.34), respectively. CONCLUSIONS: In cancer patients with septic shock, this trial did not demonstrate superiority of liberal over restrictive transfusion strategy. The absence of mortality benefit and the uncertainty surrounding the observed imbalance in adverse events do not support the routine preference of either transfusion strategy over the other.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive-Réanimation, Medical Intensive Care Unit, Hôpital Cochin, Université Paris Cité, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France. frederi…
- Assistance Publique - Hôpitaux de Paris, Medical Intensive Care Unit, Hôpital Cochin, Université Paris Cité, Paris, France.
- Assistance Publique - Hôpitaux de Paris, Medical Intensive Care Unit, Hôpital Saint-Louis, Université Paris Cité, Paris, France.
- Department of Anesthesiology and Critical Care, Institut Paoli-Calmettes, Marseille, France.
- Medical Intensive Care Unit, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France.
- Medical Intensive Care Unit, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.
Förderung
- French Ministry of Health
Zitieren
APA
Pène, F., Vigneron, C., Lafarge, A., Mokart, D., Zerbib, Y., Canet, E., Kamel, T., Moreau, A. S., Cadoz, C., Decavèle, M., Mekontso Dessap, A., Ebstein, N., Lacave, G., Chelly, J., Reuter, D., Argaud, L., Ait-Oufella, H., Bigé, N., Levrard, M., …, & GRRR-OH (Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique) (2026). Early red blood cell transfusion strategy in septic shock among patients with cancer: the TRANSPORT randomized controlled trial. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08582-4
Vancouver
Pène F, Vigneron C, Lafarge A, Mokart D, Zerbib Y, Canet E, et al. Early red blood cell transfusion strategy in septic shock among patients with cancer: the TRANSPORT randomized controlled trial. Intensive Care Medicine. 2026. doi:10.1007/s00134-026-08582-4
BibTeX
@article{Pne2026,
author = {Pène, Frédéric and Vigneron, Clara and Lafarge, Antoine and Mokart, Djamel and Zerbib, Yoann and Canet, Emmanuel and Kamel, Toufik and Moreau, Anne-Sophie and Cadoz, Cyril and Decavèle, Maxens and Mekontso Dessap, Armand and Ebstein, Nathan and Lacave, Guillaume and Chelly, Jonathan and Reuter, Danielle and Argaud, Laurent and Ait-Oufella, Hafid and Bigé, Naïke and Levrard, Mélanie and Charpentier, Julien and Bisbal, Magali and Maizel, Julien and Benguerfi, Soraya and Barbier, François and Bureau, Côme and Bigot, Noémie and Resche-Rigon, Matthieu and Lambert, Jérôme and Azoulay, Elie and GRRR-OH (Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique), GRRR-OH (Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique)},
title = {Early red blood cell transfusion strategy in septic shock among patients with cancer: the TRANSPORT randomized controlled trial},
journal = {Intensive Care Medicine},
year = {2026},
doi = {10.1007/s00134-026-08582-4}
}
EUVIMED